MODIFIABLE RISK FACTORS FOR ADVERSE OUTCOMES IN SLE
SLE 不良后果的可改变风险因素
基本信息
- 批准号:6302993
- 负责人:
- 金额:$ 2.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-12-01 至 2000-11-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The objective of this investigation is to prospectively confirm previously examined risk factors for adverse outcomes in Systemic Lupus Erythematosus (SLE). Modifiable risk factors have been shown to impact on both the disease activity, as measured by the SLAM as well as health status assessed by SF 36 in SLE. We aim to confirm that potentially modifiable risk factors such as self-efficacy and social support do effect disease activity (SLAM) and health status (SF36). Cardiovascular disease results in excess morbidity and mortality in young women with SLE. We plan to study the variation in cardiovascular risk factor management (risk factor detection and appropriateness of management according to published guidelines) in patients with SLE. We also plan to look at the association between cardiovascular risk factor management, SLE-specific factors, socio-demographic and psychosocial factors and : a) intermediate outcomes including smoking, hypertension, hyperlipidemia, sedentary lifestyle, obesity and diabetes; and b) cardiovascular events including angina, myocardial infarction, congestive heart failure and stroke. The basic design of the proposed study is a prospective follow-up of 40 patients who were first evaluated between 1989 and 1994. Each patient will be asked to fill out a questionnaire by mail. After this subjects will come to the clinic for a physician assessment of disease activity (SLAM). Disease activity will be measured 6 months later using the SA-SLAM and physical and mental health will be measured by the SF36. This will be filled out by mail with telephone or home visit follow-up for non-respondents. Subjects will be asked to release all medical records regarding their care from all providers and hospitals since their diagnosis of lupus, and for relevant problems prior to diagnosis. The records will be reviewed for cardiovascular risk factors.
本研究的目的是前瞻性地证实先前研究的系统性红斑狼疮(SLE)不良结局的风险因素。 可改变的风险因素已被证明会影响疾病活动,如SLAM所测量的,以及SF 36评估的SLE健康状况。 我们的目的是证实潜在的可改变的风险因素,如自我效能和社会支持确实影响疾病活动(SLAM)和健康状况(SF 36)。 心血管疾病导致SLE年轻女性发病率和死亡率过高。 我们计划研究SLE患者心血管危险因素管理(根据已发表的指南进行危险因素检测和适当管理)的变化。 我们还计划研究心血管风险因素管理、SLE特异性因素、社会人口学和心理社会因素与以下因素之间的关联:a)中间结局,包括吸烟、高血压、高脂血症、久坐不动的生活方式、肥胖和糖尿病;和B)心血管事件,包括心绞痛、心肌梗死、充血性心力衰竭和卒中。这项研究的基本设计是对1989年至1994年间首次接受评估的40名患者进行前瞻性随访。 每位患者将被要求通过邮件填写一份调查问卷。 之后,受试者将前往诊所接受医生的疾病活动性评估(SLAM)。6个月后将使用SA-SLAM测量疾病活动度,并通过SF 36测量身心健康。 这将通过邮件填写,对于非应答者,将通过电话或家庭访视进行随访。 将要求受试者自诊断狼疮以来,以及诊断前的相关问题,从所有提供者和医院发布有关其护理的所有医疗记录。 将审查记录中的心血管风险因素。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Graciela S Alarcon其他文献
Graciela S Alarcon的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Graciela S Alarcon', 18)}}的其他基金
EFFECT OF SYSTEMIC LUPUS ERYTHMATOSUS IN MINORITIES
系统性红斑狼疮对少数族裔的影响
- 批准号:
7603162 - 财政年份:2007
- 资助金额:
$ 2.95万 - 项目类别:
EFFECT OF SYSTEMIC LUPUS ERYTHMATOSUS IN MINORITIES
系统性红斑狼疮对少数族裔的影响
- 批准号:
7380394 - 财政年份:2006
- 资助金额:
$ 2.95万 - 项目类别:
ACR RE-CLASSIFICATION OF SLE CRITERIA (AROSE) ORIG GRANT REVISION OF ACR CLASSIF
ACR SLE 标准重新分类 (AROSE) 原始拨款修订 ACR 分类
- 批准号:
7380477 - 财政年份:2006
- 资助金额:
$ 2.95万 - 项目类别:
EFFECT OF SYSTEMIC LUPUS ERYTHMATOSUS IN MINORITIES
系统性红斑狼疮对少数族裔的影响
- 批准号:
7198514 - 财政年份:2005
- 资助金额:
$ 2.95万 - 项目类别:
Effect of systemic lupus erythmatosus in minorities
系统性红斑狼疮对少数族裔的影响
- 批准号:
6980477 - 财政年份:2004
- 资助金额:
$ 2.95万 - 项目类别:
MODIFIABLE RISK FACTORS FOR ADVERSE OUTCOMES IN SLE
SLE 不良后果的可改变风险因素
- 批准号:
6565383 - 财政年份:2001
- 资助金额:
$ 2.95万 - 项目类别:
GENETIC RISK PROFILE IN LONGITUDINAL SLE COHORTS
纵向 SLE 队列中的遗传风险概况
- 批准号:
6493284 - 财政年份:2001
- 资助金额:
$ 2.95万 - 项目类别:
MODIFIABLE RISK FACTORS FOR ADVERSE OUTCOMES IN SLE
SLE 不良后果的可改变风险因素
- 批准号:
6410699 - 财政年份:2000
- 资助金额:
$ 2.95万 - 项目类别:
GENETIC RISK PROFILE IN LONGITUDINAL SLE COHORTS
纵向 SLE 队列中的遗传风险概况
- 批准号:
6348946 - 财政年份:2000
- 资助金额:
$ 2.95万 - 项目类别:
GENETIC RISK PROFILE IN LONGITUDINAL SLE COHORTS
纵向 SLE 队列中的遗传风险概况
- 批准号:
6201555 - 财政年份:1999
- 资助金额:
$ 2.95万 - 项目类别:
相似海外基金
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 2.95万 - 项目类别:
CAPRISA CASCADE Clinical Trials Network Clinical Research Site
CAPRISA CASCADE 临床试验网络临床研究网站
- 批准号:
10754981 - 财政年份:2023
- 资助金额:
$ 2.95万 - 项目类别:
TO PROVIDE BIO-MEDICAL AND BEHAVIORAL RESEARCH RESOURCES AND CLINICAL RESEARCH COORDINATING SERVICES TO SUPPORT THE NIDA CLINICAL TRIALS NETWORK (CTN)
提供生物医学和行为研究资源以及临床研究协调服务以支持 NIDA 临床试验网络 (CTN)
- 批准号:
10617997 - 财政年份:2022
- 资助金额:
$ 2.95万 - 项目类别:
TO PROVIDE BIO-MEDICAL AND BEHAVIORAL RESEARCH RESOURCES AND CLINICAL RESEARCH COORDINATING SERVICES TO SUPPORT THE NIDA CLINICAL TRIALS NETWORK (CTN)
提供生物医学和行为研究资源以及临床研究协调服务以支持 NIDA 临床试验网络 (CTN)
- 批准号:
10538151 - 财政年份:2021
- 资助金额:
$ 2.95万 - 项目类别:
Admin. Supp. for NCI P30 Cancer Center Grants to Facilitate the Development of Standardized Electronic Treatment Plan Builds for NCI-Supported Clinical Trials Applicable Across Clinical Research Sites
行政。
- 批准号:
10442122 - 财政年份:2021
- 资助金额:
$ 2.95万 - 项目类别:
Health 360x Clinical Research Platform for Scalable Access to Clinical Trials
Health 360x 临床研究平台可扩展临床试验的访问
- 批准号:
10624966 - 财政年份:2021
- 资助金额:
$ 2.95万 - 项目类别:
Health 360x Clinical Research Platform for Scalable Access to Clinical Trials
Health 360x 临床研究平台可扩展临床试验的访问
- 批准号:
10515803 - 财政年份:2021
- 资助金额:
$ 2.95万 - 项目类别:
Health 360x Clinical Research Platform for Scalable Access to Clinical Trials
Health 360x 临床研究平台可扩展临床试验的访问
- 批准号:
10258627 - 财政年份:2021
- 资助金额:
$ 2.95万 - 项目类别:
New Mexico Clinical Trials Node: Clinical research and practice to address substance use in diverse, rural and underserved populations
新墨西哥州临床试验节点:解决多样化、农村和服务不足人群的药物使用问题的临床研究和实践
- 批准号:
10581505 - 财政年份:2019
- 资助金额:
$ 2.95万 - 项目类别:
New Mexico Clinical Trials Node: Clinical research and practice to address substance use in diverse, rural and underserved populations
新墨西哥州临床试验节点:解决多样化、农村和服务不足人群的药物使用问题的临床研究和实践
- 批准号:
10379715 - 财政年份:2019
- 资助金额:
$ 2.95万 - 项目类别: